Facts that Destroy Shorts_老虎社区_美港股上老虎

Facts that Destroy Shorts

qwertd
2021-12-22

$Cassava Sciences Inc(SAVA)$ Facts that Destroy Shorts:1. SavaDx being used as an unvalidated biomarker diagnostic in CMS and Phase 3 trials.2. Yale replicating binding of simufilam to FLNA by screening other molecules for FLNA binding affinity.3. Yale showing FLNA conformational activity in a publication supporting Sava’s altered FLNA observation.4. Yale showing correlation of FLNA in AD in mouse model.5. Phase 3 currently recruiting and dosing.6. Using the Shorts theoretical DPM equation using the correct 0.1 mg of protein instead of the incorrect 0.1 ug used by shorts (consistent with other Sava assays) giving the correct theoretical 47,000 DPMs and confirming femtomolar binding of simufilam to FLNA…thank you shorts 😂.7. Safety and clinical efficacy data from many stakeholders and chain of custody shown for 12 month data.8. Two separate Journals stating no data manipulation

免责声明：上述内容仅代表发帖人个人观点，不构成本平台的任何投资建议。

推荐
最新

暂无评论

热议股票

关于我们·老虎社区守则·老虎社区账号管理规范·老虎社区服务协议·老虎社区隐私政策

公司名称：北京至简风宜信息技术有限公司

违法和不良信息投诉：010-5681-3562（工作时间9:30-18:30）

邮箱：service@laohu8.com

营业执照：91110105MA01A4U55R

ICP备：京ICP备18016422号

网安备：京公网安备11010502036490

关注我们

{"i18n":{"language":"zh_CN"},"data":{"magic":2,"id":691154596,"tweetId":"691154596","gmtCreate":1640154178331,"gmtModify":1640154358428,"author":{"id":3479274696871559,"authorId":3479274696871559,"authorIdStr":"3479274696871559","name":"qwertd","avatar":"https://static.tigerbbs.com/c919127bf800db36898f470027bd6e99","vip":8,"userType":8,"introduction":"运营账号","boolIsFan":false,"boolIsHead":false,"crmLevel":1,"crmLevelSwitch":0,"individualDisplayBadges":[],"fanSize":85,"starInvestorFlag":false},"themes":[],"images":[],"coverImages":[],"title":"Facts that Destroy Shorts","extraTitle":"","html":"<html><head></head><body><p><a href=\"https://laohu8.com/S/SAVA\">$Cassava Sciences Inc(SAVA)$</a> Facts that Destroy Shorts:1. SavaDx being used as an unvalidated biomarker diagnostic in CMS and Phase 3 trials.2. Yale replicating binding of simufilam to FLNA by screening other molecules for FLNA binding affinity.3. Yale showing FLNA conformational activity in a publication supporting Sava’s altered FLNA observation.4. Yale showing correlation of FLNA in AD in mouse model.5. Phase 3 currently recruiting and dosing.6. Using the Shorts theoretical DPM equation using the correct 0.1 mg of protein instead of the incorrect 0.1 ug used by shorts (consistent with other Sava assays) giving the correct theoretical 47,000 DPMs and confirming femtomolar binding of simufilam to FLNA…thank you shorts 😂.7. Safety and clinical efficacy data from many stakeholders and chain of custody shown for 12 month data.8. Two separate Journals stating no data manipulation</p></body></html>","htmlText":"<html><head></head><body><p><a href=\"https://laohu8.com/S/SAVA\">$Cassava Sciences Inc(SAVA)$</a> Facts that Destroy Shorts:1. SavaDx being used as an unvalidated biomarker diagnostic in CMS and Phase 3 trials.2. Yale replicating binding of simufilam to FLNA by screening other molecules for FLNA binding affinity.3. Yale showing FLNA conformational activity in a publication supporting Sava’s altered FLNA observation.4. Yale showing correlation of FLNA in AD in mouse model.5. Phase 3 currently recruiting and dosing.6. Using the Shorts theoretical DPM equation using the correct 0.1 mg of protein instead of the incorrect 0.1 ug used by shorts (consistent with other Sava assays) giving the correct theoretical 47,000 DPMs and confirming femtomolar binding of simufilam to FLNA…thank you shorts 😂.7. Safety and clinical efficacy data from many stakeholders and chain of custody shown for 12 month data.8. Two separate Journals stating no data manipulation</p></body></html>","text":"$Cassava Sciences Inc(SAVA)$ Facts that Destroy Shorts:1. SavaDx being used as an unvalidated biomarker diagnostic in CMS and Phase 3 trials.2. Yale replicating binding of simufilam to FLNA by screening other molecules for FLNA binding affinity.3. Yale showing FLNA conformational activity in a publication supporting Sava’s altered FLNA observation.4. Yale showing correlation of FLNA in AD in mouse model.5. Phase 3 currently recruiting and dosing.6. Using the Shorts theoretical DPM equation using the correct 0.1 mg of protein instead of the incorrect 0.1 ug used by shorts (consistent with other Sava assays) giving the correct theoretical 47,000 DPMs and confirming femtomolar binding of simufilam to FLNA…thank you shorts 😂.7. Safety and clinical efficacy data from many stakeholders and chain of custody shown for 12 month data.8. Two separate Journals stating no data manipulation","highlighted":1,"essential":1,"paper":2,"likeSize":1,"commentSize":0,"repostSize":0,"favoriteSize":0,"link":"https://laohu8.com/post/691154596","repostId":0,"isVote":1,"tweetType":1,"viewCount":1591,"commentLimit":10,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"symbols":["SAVA"],"verified":2,"subType":0,"readableState":1,"langContent":"CN","currentLanguage":"CN","warmUpFlag":false,"orderFlag":false,"shareable":true,"causeOfNotShareable":"","featuresForAnalytics":[],"commentAndTweetFlag":false,"upFlag":false,"length":758,"xxTargetLangEnum":"ZH_CN"},"commentList":[],"hasMoreComment":false,"orderType":2}